The Latest News

Application Guidelines Asian Fund for Cancer Research

Application Guidelines Asian Fund for Cancer Research

Funding Period: April 1, 2017 – March 31, 2019 October, 2016


浙江省肿瘤防治联盟成立 美尊医询升级中美医疗沟通效率


2016年10月15-16日,由中国肿瘤防治联盟浙江省联盟筹委会与浙江省肿瘤靶向治疗技术指导中心筹委会共同主办,美中抗癌协会(USCACA)协办的中国肿瘤防治联盟浙江省联盟暨浙江省肿瘤靶向治疗技术指导中心成立大会,在浙江杭州邵逸夫医院下沙院区圆满召开。近200位顶级肿瘤专科专家参会。作为专注于管理中美肿瘤治疗资源的移动智慧医疗服务平台,美尊医询全程助力大会召开,连接美方高端专家资源,提升中美医学交流水平!


行业聚焦:打造中美肿瘤医疗连接平台的呼声


Partnership for 5 more years

Dr. George Wilding, a Board Member of USCACA and the Vice Provost of MD Anderson Cancer Center, led a delegation to attend the 2nd International Conference on Translational Cancer Research held in Tianjin during August 2016. Dr. Wilding and Dr. Ping Wang, the President of Tianjin Medical University Cancer Hospital and Institute, also signed an Agreement to continue the Sister Institute Relationship for 5 additional years after 10 years’ highly successful partnership.


VIP keynote Speaker Invitation


USCACA is an endorser of the World Precision Medicine Summit 2016 to be held in Shanghai during December 3-4. Dr.Wei Zhang will serve as a moderator and panel discussant.USCACA friend, the Director of Wake Forest Cancer Center, Dr. Boris Pasche will deliver a keynote speech on precision oncology initiative at Wake Forest.


第四届国际肿瘤大会

USCACA,NFCR,AFCR 2016 Scholar Awards

U.S. Chinese Anti-Cancer Association (USCACA, 美中抗癌协会)

National Foundation for Cancer Research (NFCR, 国家癌症基金-美国)

Asia Fund for Cancer Research (AFCR, 亚州癌症研究基金会)

2016 Scholar Awards


AACR will be holding the Second Shanghai Conference during November 12-15

AACR will be holding the Second Shanghai Conference entitled "New Horizons in Cancer Research" during November 12-15 in Shanghai, China. Our Board of Directors, Dr. Wei Zhang, serves on the Regional Advisory Committee and has been invited to give two presentations on cancer genomics at the conference.

The first Impact Factor of CJC is 2.155.

We are pleased to announce that the first Impact Factor of CJC is 2.155 !

Last year, the Chinese Journal of Cancer (CJC) was accepted in the Science Citation Index Expanded (SCI-E) by Thomson Reuters.

It has then been granted an Impact Factor of 2.155 for the of 2014, reflecting the citations during the year 2014 of articles published in 2012 and 2013.

Lung cancer and its prevalence in China: an Editor Q+A

Cases of lung cancer in China are rising, but why is this? Editors of a new series on lung cancer, Li Yan and Wei Zhang, explain why occurrence of lung cancer is increasing in China and the work that is being done to prevent this.

http://blogs.biomedcentral.com/on-medicine/2015/08/05/lung-cancer-preval...

Pages